Dr. Gary Smith

Gary Smith


Special Interests:

Prostate stem cells and angiogenesis Targets for new therapies for prevention and treatment of prostate cancer Racial differences in prostate cancer mortality

About Me


Dr. Gary Smith joined the staff of Roswell Park Comprehensive Cancer Center (Roswell Park) in 2006 as Co-Leader of the Prostate Program for the Roswell Park Cancer Center Support (Core) Grant, in the Department of Urologic Oncology. He comes to Roswell Park from the University of North Carolina at Chapel Hill, where he served as Professor in the Department of Pathology and Laboratory Medicine since 1996.

Dr. Smith earned his doctorate in genetics from North Carolina State University in 1975. He completed postdoctoral training at the Lineberger Comprehensive Cancer Center in 1977 and Environmental Pathology in 1978.

Dr. Smith is a co-founder of AndroBioSys, Inc. which is pioneering new human tissue-based models for drug testing and developing new treatments for prostate disease.

He has authored or co-authored more than 70 journal articles and book chapters.



Roswell Park Comprehensive Cancer Center
  • Distinguished Professor, Oncology
  • Department of Urologic Oncology
AndroBioSys, Inc.
  • Chief Science Officer


Education and Training:

  • PhD (Genetics) North Carolina State University
  • Post-doc Lineberger Comprehensive Cancer Center, 1977

Professional Memberships:

  • American Association of Pathologists
  • American Association of Cancer Research


Research Overview:

Dr. Smith’s research interests focus on prostate stem cells and angiogenesis, and whether these provide targets for new therapies for prevention and treatment of prostate cancer, and on racial differences in prostate cancer mortality.


Godoy A, Salazar K, Figueroa C, Smith GJ, de los Angeles Garcia M, Nualart FJ. Nutritional channels in breast cancer. Journal of cellular and molecular medicine 2009; 13(9B):3973-3984

Mathew G, Timm Jr EA, Sotomayor P, Godoy A, Montecinos VP, Smith GJ, Huss WJ. ABCG2-mediated DyeCycle Violet efflux defined side population in benign and malignant prostate. Cell cycle (Georgetown, Tex.) 2009; 8(7):1053-1061

Morrison C, Cheney R, Johnson CS, Smith G, Mohler JL. Central quadrant procurement of radical prostatectomy specimens. Prostate 2009; 69(7):770-773

Sotomayor P, Godoy A, Smith GJ, Huss WJ. Oct4A is expressed by a subpopulation of prostate neuroendocrine cells. Prostate 2009; 69(4):401-410

Godoy A, Montecinos VP, Gray DR, Sotomayor P, Yau JM, Vethanayagam RR, Singh S, Mohler JL, Smith GJ. Androgen deprivation induces rapid involution and recovery of human prostate vasculature. American journal of physiology. Endocrinology and metabolism 2011; 300(2):E263-E275

Tanner MJ, Welliver Jr RC, Chen M, Shtutman M, Godoy A, Smith G, Mian BM, Buttyan R. Effects of androgen receptor and androgen on gene expression in prostate stromal fibroblasts and paracrine signaling to prostate cancer cells.PloS one 2011; 6(1):e16027

Xu Z, Bensen JT, Smith GJ, Mohler JL, Taylor JA. GWAS SNP Replication among African American and European American men in the North Carolina-Louisiana prostate cancer project (PCaP). Prostate 2011; 71(8):881-891

Godoy A, Watts A, Sotomayor P, Montecinos VP, Huss WJ, Onate SA, Smith GJ. Androgen receptor is causally involved in the homeostasis of the human prostate endothelial cell. Endocrinology 2008; 149(6):2959-2969

Satheesh Babu AK, Vijayalakshmi MA, Smith GJ, Chadha KC. Thiophilic-interaction chromatography of enzymatically active tissue prostate-specific antigen (T-PSA) and its modulation by zinc ions. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2008; 861(2):227-235

Huss WJ, Gray DR, Tavakoli K, Marmillion ME, Durham LE, Johnson MA, Greenberg NM, Smith GJ. Origin of androgen-insensitive poorly differentiated tumors in the transgenic adenocarcinoma of mouse prostate model. Neoplasia (New York, N.Y.) 2007; 9(11):938-950

Chadha KC, Nair BB, Chakravarthi S, Zhou R, Godoy A, Mohler JL, Aalinkeel R, Schwartz SA, Smith GJ. Enzymatic activity of free-prostate-specific antigen (f-PSA) is not required for some of its physiological activities. Prostate 2011;71(15):1680-1690

Godoy AS, Sotomayor P, Warts A, Montecinos VP, Vethanayagam RR, Smith GJ. Androgen-ablation modulates human prostate endothelial cell phenotype.Proceedings of the American Association for Cancer Research Annual Meeting2008; 49:257

Godoy AS, Watts A, Sotomayor PC, Montecinos VP, Huss WJ, Smith GJ.Functional characterization of androgen receptor in human prostate endothelial cells. Proceedings of the American Association for Cancer Research Annual Meeting 2007; 48:1094

Godoy AS, Watts A, Sotomayor PC, Montecinos VP, Onate SA, Huss WJ,Smith GJ. Human prostate endothelial cells as a first-line target for androgens.BJU international 2007; 100(Suppl. 3):8

Mathew G, Timm EA, Karasik E, Montecinos VP, Smith GJ, Foster BA, Huss WJ. ABCG2 expressing prostate cancer cells regenerate prostate tumors in vivo. Proceedings of the American Association for Cancer Research Annual Meeting 2008; 49:478-479

Matta KL, Chandrasekaran EV, Mohler JL, Smith GJ, Lau JT. An untested and new approach towards the development of glycosylation-related cancer signatures. BJU international 2007; 100(Suppl. 3):32

Montecinos VP, Godoy AS, Stafford JA, Huss WJ, Smith GJ. Rapid angiogenesis in an in vivo model of primary human prostate xenografts.Proceedings of the American Association for Cancer Research Annual Meeting2007; 48:725

Montecinos VP, Stafford J, Godoy A, Smith GJ. Role of microenvironmental VEGF distribution in human prostate angiogenesis. BJU international 2007;100(Suppl. 3):33

Parker FL, Marshall JR, Smith GJ. Validation of self-reported race using the sequenom massarray compact system to quantitatively determine genomic ancestry. BJU international 2007; 100(Suppl. 3):34

Parker FL, Marshall JR, Smith GJ. Validation of self-reported race using the Sequenom MassArray compact system to quantitavely determine genomic ancestry. Proceedings of the American Association for Cancer Research Annual Meeting 2008; 49:911

Sotomayor P, Godoy A, Smith G, Huss W. Oct4 expression in benign and prostate cancer neuroendocrine cells. BJU international 2007; 100(Suppl. 3):40

Montecinos VP, Godoy A, Hinklin J, Vethanayagam RR, Smith GJ. Primary xenografts of human prostate tissue as a model to study angiogenesis induced by reactive stroma. PloS one 2012; 7(1):e29623

Wang X, Xu Z, Chrysovergis K, Bienstock R, Shim M, Bensen JT, Fontham E,Smith GJ, Mohler J, Taylor J, Eling TE. The dual effects of H6D polymorphism of NAG-1/GDF15 in prostate cancer carcinogenesis. Proceedings of the American Association for Cancer Research Annual Meeting 2011; 52:Abstract #5541

Sucheston LE, Bensen JT, Xu Z, Singh PK, Preus L, Mohler JL, Su LJ, Fontham ET, Ruiz B, Smith GJ, Taylor JA. Genetic ancestry, self-reported race and ethnicity in african americans and european americans in the PCaP cohort. PloS one 2012; 7(3):e30950